Therapy Detail

Therapy Name Dexamethasone + Filgrastim + Palifermin + Rituximab
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Dexamethasone Adexone Desametasone
Filgrastim Neupogen G-CSF Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary).
Palifermin Kepivance FGF-7 Kepivance (palifermin) is a recombinant human keratinocyte growth factor, which stimulates epithelial cell proliferation and differentiation (PMID: 24151975).
Rituximab Rituxan IDEC-C2B8 CD20 Antibody 3 Rituxan (rituximab) is a chimeric mononclonal CD20-targeted antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent cytotoxicity and antibody-dependent cellular cytoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02961816 Phase II Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Withdrawn